药明巨诺-B再涨超6%，CAR-T产品在澳门获批上市，有望带动销售收入增长

智通财经网2025-06-20

周五（6月20日），药明巨诺-B再涨超6%，CAR-T产品在澳门获批上市，有望带动销售收入增长。消息面上，6月4日，药明巨诺宣布，其自主开发的靶向CD19自体CAR-T细胞免疫治疗产品瑞基奥仑赛注射液的新药上市许可申请（NDA）获得中国澳门药物监督管理局批准。公司上月底也曾公布，国家药监局已受理细胞免疫治疗产品倍诺达(瑞基奥仑赛注射液)用于二线治疗复发或难治成人大B细胞淋巴瘤(r/r LBCL)...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1173100399?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/33329fee89594035f188db32eff79516","is_english":false,"pubTime":"2025-06-20 11:50","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"1173100399","market":"us","top_or_hot":-1,"title":"药明巨诺-B再涨超6%，CAR-T产品在澳门获批上市，有望带动销售收入增长","media":"智通财经网","content":"<div>\n<p>周五（6月20日），药明巨诺-B再涨超6%，CAR-T产品在澳门获批上市，有望带动销售收入增长。消息面上，6月4日，药明巨诺宣布，其自主开发的靶向CD19自体CAR-T细胞免疫治疗产品瑞基奥仑赛注射液的新药上市许可申请（NDA）获得中国澳门药物监督管理局批准。公司上月底也曾公布，国家药监局已受理细胞免疫治疗产品倍诺达(瑞基奥仑赛注射液)用于二线治疗复发或难治成人大B细胞淋巴瘤(r/r LBCL)...</p>\n\n<a href=\"https://www.zhitongcaijing.com/content/detail/1307605.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>药明巨诺-B再涨超6%，CAR-T产品在澳门获批上市，有望带动销售收入增长</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n药明巨诺-B再涨超6%，CAR-T产品在澳门获批上市，有望带动销售收入增长\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-20 11:50 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/content/detail/1307605.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>周五（6月20日），药明巨诺-B再涨超6%，CAR-T产品在澳门获批上市，有望带动销售收入增长。消息面上，6月4日，药明巨诺宣布，其自主开发的靶向CD19自体CAR-T细胞免疫治疗产品瑞基奥仑赛注射液的新药上市许可申请（NDA）获得中国澳门药物监督管理局批准。公司上月底也曾公布，国家药监局已受理细胞免疫治疗产品倍诺达(瑞基奥仑赛注射液)用于二线治疗复发或难治成人大B细胞淋巴瘤(r/r LBCL)...</p>\n\n<a href=\"https://www.zhitongcaijing.com/content/detail/1307605.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02126","symbol_name":"药明巨诺-B","start_time":0,"source_url":"https://www.zhitongcaijing.com/content/detail/1307605.html","article_id":"1173100399","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/33329fee89594035f188db32eff79516"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173100399","pubTimestamp":1750391401,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"周五，药明巨诺-B再涨超6%，CAR-T产品在澳门获批上市，有望带动销售收入增长。消息面上，6月4日，药明巨诺宣布，其自主开发的靶向CD19自体CAR-T细胞免疫治疗产品瑞基奥仑赛注射液的新药上市许可申请获得中国澳门药物监督管理局批准。公司预计下一期间倍诺达的销售收入会再次增加，倍诺达具有卓越的产品特性，可为患者带来突破性价值，并预期更多的适应症获批准。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02126":"药明巨诺-B"},"translate_title":"WuXi Juno-B rose by more than 6%, and CAR-T products were approved for listing in Macau, which is expected to drive sales revenue growth","themeId":"51c727b056d2ee2a0c19ce4dee409c50","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/5a5d62e2c481b271dc377c9c465f3f4e","symbols_score_info":{"02126":1.1},"content_text":"周五（6月20日），药明巨诺-B再涨超6%，CAR-T产品在澳门获批上市，有望带动销售收入增长。消息面上，6月4日，药明巨诺宣布，其自主开发的靶向CD19自体CAR-T细胞免疫治疗产品瑞基奥仑赛注射液的新药上市许可申请（NDA）获得中国澳门药物监督管理局批准。公司上月底也曾公布，国家药监局已受理细胞免疫治疗产品倍诺达(瑞基奥仑赛注射液)用于二线治疗复发或难治成人大B细胞淋巴瘤(r/r LBCL)患者的新适应症上市许可申请。公司此前表示，2024年下半年，公司的商业团队在人员与架构方面均进行了调整。目前已建立强劲的商业团队，负责倍诺达在中国的商业化。商业团队具备强大的商业化能力，涵盖销售团队、市场团队、市场准入及创新支付团队以及 CAR-T顾问团队。公司预计下一期间倍诺达的销售收入会再次增加，倍诺达具有卓越的产品特性，可为患者带来突破性价值，并预期更多的适应症获批准。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173100399","isCrawlerRequest":true}